The global biopsy devices market was valued at US$ 2.68 billion in 2025 and is projected to reach US$ 4.84 billion by 2035, expanding at a CAGR of 6.1% during the forecast period. The market supports a clinically essential diagnostic workflow in which tissue or cell samples are collected for histopathological and cytological evaluation, enabling accurate disease identification and treatment planning. Demand is primarily anchored in cancer diagnosis and confirmation pathways, while the growing preference for minimally invasive procedures is broadening the adoption of image-guided sampling technologies, single-use biopsy components, and outpatient-compatible procedural solutions.
Rising cancer incidence, an ageing global population, and the increasing volume of diagnostic and screening procedures are expected to remain the principal demand drivers. Biopsy procedures play a critical role in confirming suspected malignancies identified through screening or diagnostic imaging, making them an integral part of cancer care rather than a direct substitute for conventional screening methods. In parallel, greater patient awareness, improvements in biopsy techniques, and wider access to diagnostic services are supporting market expansion. Technological advances that improve sampling precision, procedural efficiency, and patient comfort are further strengthening the role of biopsy devices across clinical settings.
Importantly, cancer-related demand is distributed across multiple anatomical sites and clinical specialties, creating a diversified opportunity for device manufacturers. Breast, lung, prostate, colorectal, and thyroid diagnostic pathways require distinct sampling approaches, supporting demand for biopsy guidance systems, needle-based biopsy guns, biopsy needles, forceps, and procedure-specific accessories. This diversity reduces the market's dependence on any single clinical specialty and allows manufacturers to address a broad range of diagnostic requirements across hospitals, diagnostic centres, and outpatient facilities.
Recent Developments
- In May 2026, Promisemed Hangzhou Meditech received FDA 510(k) clearance for its VeriEcto Automatic Biopsy Needles, designed for obtaining tissue samples from soft tissues, including the liver, kidney, prostate, breast, and lymph nodes. The sterile, single-use device uses a spring-loaded mechanism to facilitate automated tissue sampling, supporting procedural efficiency and infection-control practices across healthcare settings. The clearance expands the availability of automated biopsy needle options and strengthens the company's presence in the biopsy devices market.
- In March 2026, Mammotome, a Danaher company, received FDA 510(k) clearance for its Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy System. Designed for use inside the MRI scanner room, the system enables MR-guided breast tissue sampling with an 8-gauge probe and an in-room operating configuration. Its shorter tubing, dual-vacuum technology, and integrated touchscreen controls are designed to streamline procedural setup and support efficient tissue collection. The development expands the availability of specialized MR-guided breast biopsy solutions and strengthens innovation in vacuum-assisted biopsy technologies.
- In September 2025, Resitu Medical AB received U.S. FDA 510(k) clearance for its RESL09 breast biopsy device, a handheld, sterile, single-use vacuum-assisted system designed for ultrasound-guided tissue sampling. The device uses vacuum fixation and electrosurgical cutting technology to retrieve large, intact breast tissue specimens for histological examination. The development highlights continued innovation in disposable, minimally invasive breast biopsy technologies and expands the range of specialized tissue-sampling solutions available to healthcare providers.
By Product Type: Global Biopsy Devices Market - Key Takeaways
- Based on product type, biopsy guidance systems accounted for the largest share of the global biopsy devices market in 2025, driven by increasing adoption of image-guided procedures and software-assisted targeting technologies. Demand is supported by the need for precise lesion localization and consistent tissue sampling across clinical settings. The segment includes conventional and robotic guidance platforms, with advanced systems gaining traction in specialized and high-acuity healthcare facilities.
- Needle-based biopsy guns retain broad clinical adoption across breast, thyroid, liver, kidney, and prostate procedures, supported by their compatibility with established diagnostic workflows. Competition focuses on tissue sample quality, ease of handling, imaging compatibility, and cost-effectiveness across vacuum-assisted, core-needle, and aspiration biopsy technologies.
- Vacuum-assisted biopsy (VAB) systems are widely used in breast biopsy procedures, enabling multiple tissue samples to be collected through a single insertion. Adoption is increasing across specialized breast centres and imaging facilities, supported by demand for efficient sampling, fewer repeat procedures, and favourable reimbursement policies, including Medicare coverage for eligible procedures in the U.S.
- Biopsy needles form a key consumable segment of the market, with demand closely linked to biopsy procedure volumes across healthcare settings. Infection-control priorities, workflow efficiency, and reduced reprocessing requirements continue to support the adoption of single-use needles, particularly in developed healthcare markets.
- Biopsy forceps demand is primarily driven by gastrointestinal endoscopy and surveillance procedures, where they play an essential role in tissue sampling. Product differentiation focuses on jaw design, sample quality, hemostatic performance, and compatibility with existing endoscopy systems.
By Application: Global Biopsy Devices Market - Key Takeaways
- Based on application, breast biopsy accounted for the largest share of the global biopsy devices market in 2025, supported by rising breast cancer incidence, expanding screening programmes, and growing awareness of early diagnosis.
- Prostate biopsy represented the second-largest application segment, driven by the increasing prevalence of prostate cancer, expanding diagnostic infrastructure, and the need for early detection. Lung biopsy also represents a significant application, playing a critical role in confirming lung cancer diagnoses and guiding treatment decisions.
- Kidney, liver, gastrointestinal, and gynecological biopsies contribute to the remaining market, supported by the growing need for tissue-based diagnosis across a broader range of diseases.
By End Use: Global Biopsy Devices Market - Key Takeaways
- Based on end use, hospitals accounted for largest share of the global biopsy devices market in 2025, driven by their capacity to perform complex biopsy procedures requiring advanced imaging, specialized clinical expertise, and post-procedure monitoring. Hospitals also lead the adoption of advanced technologies, including robotic and AI-enabled biopsy guidance systems, supported by established infrastructure and multidisciplinary care capabilities.
- Ambulatory Surgical Centers (ASCs) are gaining importance as healthcare providers shift eligible procedures toward cost-efficient outpatient settings. Demand is supported by the need for compact biopsy systems, simplified workflows, and single-use products that improve operational efficiency and patient convenience across multi-specialty facilities.
By Region: Global Biopsy Devices Market - Key Takeaways
- North America dominated the global biopsy devices market in 2025, supported by established cancer-screening infrastructure, broad reimbursement coverage, and strong adoption of advanced diagnostic technologies. The region benefits from a concentration of leading healthcare institutions and academic centres that drive early adoption of innovations such as AI-assisted imaging, robotic bronchoscopy, and advanced biopsy needles. Its mature healthcare infrastructure supports consistent demand through equipment upgrades, replacement cycles, disposable replenishment, and the growing volume of outpatient biopsy procedures.
- Europe represents a significant market for biopsy devices, supported by organized cancer-screening programmes, established oncology care pathways, and extensive imaging and endoscopy infrastructure. Germany dominates the regional market, driven by its well-developed hospital infrastructure, strong diagnostic capabilities, and established oncology network.
- Asia-Pacific is expected to be the fastest-growing regional market for biopsy devices, driven by expanding healthcare infrastructure, improving access to diagnostic services, and rising adoption of image-guided and vacuum-assisted biopsy technologies. Increasing investments in oncology facilities and wider cancer-screening initiatives across China, India, and Southeast Asia are expanding demand for biopsy procedures. China's growing network of regional oncology centres, India's healthcare infrastructure development, and the expansion of private hospital networks across Southeast Asia are further supporting market growth.
iGATE RESEARCH report titled "Biopsy Devices Market (By Product Type, Application, End Use, and Region), Key Company Profiles, Competitive Landscape, Market Dynamics, Trends and Recent Developments - Global Forecast to 2035" provides a comprehensive analysis of the Global Biopsy Devices Market.
This report has been analyzed from 11 View Points:
(1) Global - Biopsy Devices Market and Forecast (2022 - 2035)
(2) Global - Biopsy Devices Market Share and Forecast (2022 - 2035)
(3) By Product Type - Global Biopsy Devices Market and Forecast (2022 - 2035)
(4) By Application - Global Biopsy Devices Market and Forecast (2022 - 2035)
(5) By End Use - Global Biopsy Devices Market and Forecast (2022 - 2035)
(6) By Region - Global Biopsy Devices Market and Forecast (2022 - 2035)
(7) By Country - Global Biopsy Devices Market and Forecast (2022 - 2035)
(8) Global Biopsy Devices Market - Key Company Profiles
(9) Global Biopsy Devices Market - Competitive Landscape
(10) Global Biopsy Devices Market - Trends & Recent Developments
(11) Global Biopsy Devices - Market Dynamics
By Product Type: Global Biopsy Devices Market and Forecast
Manual Biopsy Guidance Systems
Robotic Biopsy Guidance Systems
Vacuum-Assisted Biopsy (VAB)
Core Needle Biopsy (CNB)
Fine-Needle Aspiration Biopsy (FNAB)
Disposable Biopsy Needles
Reusable Biopsy Needles
General
Hot/Diathermy
By Application: Global Biopsy Devices Market and Forecast
- Breast Biopsy
- Prostate Biopsy
- Lung Biopsy
- Kidney Biopsy
- Liver Biopsy
- Gastroenterology Biopsy
- Gynecological Biopsy
- Other Applications
By End-Use: Global Biopsy Devices Market and Forecast
- Hospitals
- Ambulatory Surgical Centers
- Other End Use
By Region: Global Biopsy Devices Market and Forecast
1. North America
2. Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
3. Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
4. Latin America
- Brazil
- Mexico
- Rest of Latin America
5. Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East and Africa
Global Biopsy Devices Market - Key Company Profiles
1. Boston Scientific
2. Hologic
3. Olympus Corporation
4. Becton, Dickinson, and Company (BD)
5. Medtronic
6. B. Braun Melsungen
7. Cook Group
8. Cardinal Health
9. Danaher
10. Stryker Corporation
11. FUJIFILM
12. Argon Medical Devices
13. Devicor Medical Products
14. INRAD
15. Merit Medical Systems
Data Source
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.